Claims for Patent: 9,340,604

Summary for Patent: 9,340,604

Title:	Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
Abstract:	This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9 M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.
Inventor(s):	Koch; Holger (Zurich, CH), Urwyler; Simon (Bern, CH), Rudolf; Michael P. (Ittigen, CH), Truong; Vu L. (Campbell, CA)
Assignee:	Aridis Pharmaceuticals, Inc. (San Jose, CA)
Application Number:	14/527,545
Patent Claims:	1. A method of producing an antibody construct or antibody fragment, the method comprising culturing a cell under conditions in which cDNA sequences are expressed; wherein the cell comprises a first cDNA sequence which encodes a heavy chain variable region and a second cDNA sequence which encodes a light chain variable region, wherein the cell produces a human antibody construct or antibody fragment comprising the heavy chain variable region and the light chain variable region, wherein the heavy chain variable region encoded by the first cDNA sequence comprises (a) a heavy chain complementarity determining region (CDR)1 comprising the amino acid sequence GASINLYD (SEQ ID NO.: 8), (b) a heavy chain CDR2 comprising the amino acid sequence GYISGST (SEQ ID NO.: 9), and (c) a heavy chain CDR3 comprising the amino acid sequence ARDVGWGPQYYYGLDV (SEQ ID NO.: 10); wherein the light chain variable region encoded by the second cDNA sequence comprises (a) a light chain CDR1 comprising the amino acid sequence HSVQSTS (SEQ ID NO.: 14), (b) a light chain CDR2 comprising the amino acid sequence GGS (SEQ ID NO.: 15), and (c) a light chain CDR3 comprising the amino acid sequence QQSDRSPPIT (SEQ ID NO.: 16), and wherein the antibody construct or antibody fragment binds with specificity to RSV F protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9 M. 2. The method of claim 1, wherein the neutralization capacity of the antibody construct or antibody fragment against at least one RSV strain is at least two times greater than the neutralization capacity of palivizumab. 3. The method of claim 1, wherein the cell is a plant cell or a mammalian cell. 4. The method of claim 1, wherein said heavy chain variable region cDNA sequence is coupled to a third cDNA sequence which encodes a constant region of human immunoglobulin. 5. The method of claim 4, wherein the third cDNA sequence is from a different patient than the first cDNA sequence and the second cDNA sequence. 6. The method of claim 4, wherein the human immunoglobulin is an IgG1. 7. The method of claim 1, wherein at least one expression vector is stably transfected into the cell and adapted to provide expression of the first cDNA sequence or the second cDNA sequence. 8. The method of claim 1, wherein at least one expression vector is transiently transfected into the cell and adapted to provide expression of the first cDNA sequence or the second cDNA sequence. 9. The method of claim 1, wherein the heavy chain variable region cDNA sequence comprises the nucleotide sequence of SEQ ID NO.: 2. 10. The method claim 1, wherein the light chain variable region cDNA sequence comprises the nucleotide sequence of SEQ ID NO.: 4. 11. The method of claim 1, wherein the first cDNA sequence comprises the nucleotide sequence of SEQ ID NO.: 5, SEQ ID NO.: 6, and/or SEQ ID NO.: 7, and further wherein the second cDNA sequence comprises the nucleotide sequence of SEQ ID NO.: 11, SEQ ID NO.: 12, and/or SEQ ID NO.: 13. 12. The method of claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO.: 1. 13. The method of claim 1, wherein the antibody construct or antibody fragment comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO.: 3. 14. The method of claim 1, wherein the antibody construct or antibody fragment recognizes the epitope of SEQ ID NO.: 23 and/or SEQ ID NO.: 24. 15. A method for treating an RSV infected patient, the method comprising administering a human antibody construct or antibody fragment to the patient, thereby treating the patient; wherein the antibody construct or antibody fragment comprises at least a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is encoded by a first cDNA sequence comprising (a) a heavy chain complementarity determining region (CDR)1 comprising the amino acid sequence GASINLYD (SEQ ID NO.: 8), (b) a heavy chain CDR2 comprising the amino acid sequence GYISGST (SEQ ID NO.: 9), and (c) a heavy chain CDR3 comprising the amino acid sequence ARDVGWGPQYYYGLDV (SEQ ID NO.: 10), wherein the light chain variable region is encoded by a second cDNA sequence comprises (a) a light chain CDR1 comprising the amino acid sequence HSVQSTS (SEQ ID NO.: 14), (b) a light chain CDR2 comprising the amino acid sequence GGS (SEQ ID NO.: 15), and (c) a light chain CDR3 comprising the amino acid sequence QQSDRSPPIT (SEQ ID NO.: 16), and wherein the antibody construct or antibody fragment binds with specificity to RSV F protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9 M. 16. The method of claim 15, wherein the human antibody construct or antibody fragment has a neutralization capacity against at least one RSV strain that is at least two times greater than the neutralization capacity of palivizumab. 17. The method of claim 15, wherein the human antibody construct or antibody fragment heavy chain variable region is coupled with a constant region of human immunoglobulin, provided that said constant region is not obtained from the same human from which the heavy chain CDR region was obtained. 18. The method of claim 15, wherein the human antibody construct or antibody fragment heavy chain variable region comprises the amino acid sequence of SEQ ID NO.: 1, and further wherein the light chain variable region comprising the amino acid sequence of SEQ ID NO.: 3. 19. The method of claim 15, wherein the human antibody construct or antibody fragment is administered with a pharmaceutically acceptable carrier, diluent, or excipient. 20. A method for preventing RSV infection in a patient at risk of infection with RSV, the method comprising administering an antibody construct or antibody fragment to the patient, thereby preventing the infection; wherein the antibody construct or antibody fragment comprises at least a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is encoded by a first cDNA sequence comprising (a) a heavy chain complementarity determining region (CDR)1 comprising the amino acid sequence GASINLYD (SEQ ID NO.: 8), (b) a heavy chain CDR2 comprising the amino acid sequence GYISGST (SEQ ID NO.: 9), and (c) a heavy chain CDR3 comprising the amino acid sequence ARDVGWGPQYYYGLDV (SEQ ID NO.: 10), wherein the light chain variable region is encoded by a second cDNA sequence comprises (a) a light chain CDR1 comprising the amino acid sequence HSVQSTS (SEQ ID NO.: 14), (b) a light chain CDR2 comprising the amino acid sequence GGS (SEQ ID NO.: 15), and (c) a light chain CDR3 comprising the amino acid sequence QQSDRSPPIT (SEQ ID NO.: 16), and wherein the antibody construct or antibody fragment binds with specificity to RSV F protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9 M. 21. The method of claim 1, wherein the light chain and heavy chain are from different antibodies produced by the patient. 22. The method of claim 4, wherein the constant region is from other than the human producing the antibodies to RSV. 23. The method of claim 1, wherein the cell comprises one or more expression vectors, wherein the one or more expression vectors comprise the first cDNA sequence or comprise the second cDNA sequence. 24. The method of claim 1, wherein the cell produces an antibody fragment. 25. The method of claim 1, wherein the antibody construct or antibody fragment neutralizes at least one RSV strain that is resistant to palivizumab. 26. The method of claim 15, wherein the antibody construct or antibody fragment neutralizes at least one RSV strain that is resistant to palivizumab.

Details for Patent 9,340,604

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2039-03-29
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2039-03-29